GlaxoSmithKline divested its portfolio of rare disease gene therapies to Orchard Therapeutics through a strategic agreement, the company announced April 12.
{iframe}https://www.beckershospitalreview.com/supply-chain/gsk-divests-line-of-rare-disease-drugs.html{/iframe}